JP2011500758A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500758A5
JP2011500758A5 JP2010530433A JP2010530433A JP2011500758A5 JP 2011500758 A5 JP2011500758 A5 JP 2011500758A5 JP 2010530433 A JP2010530433 A JP 2010530433A JP 2010530433 A JP2010530433 A JP 2010530433A JP 2011500758 A5 JP2011500758 A5 JP 2011500758A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
alkyloxy
hydroxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530433A
Other languages
English (en)
Japanese (ja)
Other versions
JP5525447B2 (ja
JP2011500758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064243 external-priority patent/WO2009053373A1/en
Publication of JP2011500758A publication Critical patent/JP2011500758A/ja
Publication of JP2011500758A5 publication Critical patent/JP2011500758A5/ja
Application granted granted Critical
Publication of JP5525447B2 publication Critical patent/JP5525447B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530433A 2007-10-26 2008-10-22 Ｐａｒｐ阻害剤としてのキノリノン誘導体 Expired - Fee Related JP5525447B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119417 2007-10-26
EP07119417.9 2007-10-26
PCT/EP2008/064243 WO2009053373A1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors

Publications (3)

Publication Number Publication Date
JP2011500758A JP2011500758A (ja) 2011-01-06
JP2011500758A5 true JP2011500758A5 (enExample) 2011-12-08
JP5525447B2 JP5525447B2 (ja) 2014-06-18

Family

ID=39345428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530433A Expired - Fee Related JP5525447B2 (ja) 2007-10-26 2008-10-22 Ｐａｒｐ阻害剤としてのキノリノン誘導体

Country Status (6)

Country Link
US (1) US8404713B2 (enExample)
EP (1) EP2215075B1 (enExample)
JP (1) JP5525447B2 (enExample)
ES (1) ES2448870T3 (enExample)
PL (1) PL2215075T3 (enExample)
WO (1) WO2009053373A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2847193B1 (en) * 2012-05-09 2019-08-07 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN107108601B (zh) * 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
KR101837047B1 (ko) * 2015-06-09 2018-03-09 제일약품주식회사 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
SG11201907774VA (en) 2017-02-24 2019-09-27 Asceneuron S A Sulfoximine glycosidase inhibitors
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
EP3672958B1 (en) 2017-08-24 2023-08-02 Asceneuron SA Annulated glycosidase inhibitors
MA53429A (fr) 2018-08-22 2022-03-30 Asceneuron Sa Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US20220143042A1 (en) 2019-02-22 2022-05-12 Asceneuron Sa Fused glycosidase inhibitors
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
EP4003358B1 (en) 2019-07-26 2025-12-31 Health Research, Inc. TREATMENT OF P53 DEFICIENCY CANCERS
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US20240208969A1 (en) * 2021-04-12 2024-06-27 Impact Therapeutics (Shanghai), Inc. Substituted fused bicyclic compounds as parp inhibitors and the use thereof
CA3216373A1 (en) 2021-04-19 2022-10-27 Lynnie TRZOSS Parp1 inhibitors and uses thereof
US20240336624A1 (en) * 2021-04-22 2024-10-10 Wigen Biomedicine Technology (shanghai) Co., Ltd. Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
WO2022222964A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
WO2022222995A1 (zh) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 吡啶酰胺类化合物
CN115232154A (zh) * 2021-04-23 2022-10-25 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN116710433A (zh) * 2021-04-23 2023-09-05 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
EP4349836A4 (en) * 2021-05-24 2024-10-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS
CN118119618A (zh) * 2021-09-09 2024-05-31 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
WO2023051812A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
EP4410791A4 (en) * 2021-09-30 2025-10-22 Xizang Haisco Pharmaceutical Co Ltd BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE
CN120058698A (zh) * 2021-10-01 2025-05-30 新特拉有限公司 氮杂环丁烷和吡咯烷parp1抑制剂及其用途
EP4421074A4 (en) * 2021-10-22 2025-12-03 Xizang Haisco Pharmaceutical Co Ltd PARP-1 DEGRADING AGENT AND ITS USE
KR20240101668A (ko) * 2021-11-19 2024-07-02 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 선택적 parp1 억제제 및 이의 용도
WO2023109521A1 (zh) * 2021-12-17 2023-06-22 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
WO2023138541A1 (zh) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
JP7607841B1 (ja) 2022-01-21 2024-12-27 シンセラ， インコーポレイテッド Ｐａｒｐ１阻害薬及びその使用
EP4469449A4 (en) * 2022-01-27 2026-02-25 Xinthera Inc PARP1 INHIBITORS AND THEIR USES
EP4460497A4 (en) * 2022-01-28 2026-01-28 Xinthera Inc PARP1 INHIBITORS AND THEIR USES
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
DK4497438T3 (da) 2022-04-28 2025-09-29 Xinthera Inc Tricykliske parp1-hæmmere og deres anvendelse
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
CN119487027A (zh) * 2022-04-28 2025-02-18 宁波新湾科技发展有限公司 作为parp1抑制剂的化合物
US20250346571A1 (en) * 2022-05-25 2025-11-13 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
US20260055104A1 (en) * 2022-08-24 2026-02-26 Haisco Pharmaceutical Group Co., Ltd. Crystal form of heteroaryl derivative parp inhibitor and use thereof
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
CN120112531A (zh) * 2022-10-20 2025-06-06 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
CN120019054A (zh) * 2022-10-20 2025-05-16 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
WO2024109871A1 (zh) 2022-11-23 2024-05-30 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025101892A1 (en) * 2023-11-10 2025-05-15 Astellas Engineered Small Molecules US, Incorporated Poly-adp ribose polymerase (parp) inhibitors and uses thereof
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (enExample) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
MA20387A1 (fr) 1984-03-26 1985-10-01 Janssen Pharmaceutica Nv Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
KR100259107B1 (ko) 1992-04-23 2000-07-01 슈테펜 엘. 네스비트 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물
TW294595B (enExample) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
BR9712023A (pt) 1996-09-10 1999-08-31 Thomae Gmbh Dr K Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
AU7548298A (en) 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6407116B1 (en) 1997-09-16 2002-06-18 Takeda Chemical Industries, Inc. Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
CA2361525C (en) 1999-01-29 2009-12-08 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
SK5212003A3 (en) 2000-10-02 2004-03-02 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
CA2456985A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
MXPA04009435A (es) 2002-03-29 2005-01-25 Janssen Pharmaceutica Nv Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico.
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AU2003284632A1 (en) * 2002-11-22 2004-06-18 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
ES2551027T3 (es) 2003-11-20 2015-11-13 Janssen Pharmaceutica Nv 2-Quinolinonas 7-fenilalquil sustituidas y 2-quinoxalinonas como inhibidores de poli(ADP-ribosa) polimerasa
ES2670349T3 (es) * 2003-11-20 2018-05-30 Janssen Pharmaceutica Nv 2-Quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de poli(ADP-ribosa) polimerasa
AU2004294354B2 (en) 2003-12-03 2009-02-19 Ym Biosciences Australia Pty Ltd Tubulin inhibitors
SG151249A1 (en) 2003-12-05 2009-04-30 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
BRPI0417571A (pt) 2003-12-10 2007-03-20 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
NZ551775A (en) 2004-06-01 2010-12-24 Univ Virginia Dual small molecule inhibitors of cancer and angiogenesis
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
KR101286969B1 (ko) 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
BRPI0607688A2 (pt) 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
AU2006283078A1 (en) 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone Analogs and methods of use thereof
NZ570014A (en) 2006-02-03 2011-04-29 Bionomics Ltd Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
KR20080094729A (ko) 2006-02-15 2008-10-23 아보트 러보러터리즈 강력한 ｐａｒｐ 억제제인 피라졸로퀴놀론
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
SI2134691T1 (sl) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2011500758A5 (enExample)
US10173998B2 (en) Antifungal compound process
AU2015231234B2 (en) Antifungal compound process
JP2017533968A5 (enExample)
JP2013542261A5 (enExample)
JP2014513110A5 (enExample)
JP2019517487A5 (enExample)
JP2016516043A5 (enExample)
JP2015503507A5 (enExample)
JP2009523760A5 (enExample)
JP2011509309A5 (enExample)
EP3119764B1 (en) Antifungal compound process
JP2016106095A (ja) イミダゾピロリジノン化合物
JP2017537949A5 (enExample)
JP2013528204A5 (enExample)
JP2015501833A5 (enExample)
JP2008500992A5 (enExample)
JP2018529687A (ja) 抗真菌化合物のプロセス
JP2016513696A5 (enExample)
EP3119746A1 (en) Antifungal compound process
JP2014505107A5 (enExample)
JP2011509302A5 (enExample)
JP2013527847A5 (enExample)
JP2020502230A5 (enExample)
JP2010514734A5 (enExample)